Publication of the ARRIVE trial of elective induction of labor for healthy low-risk nulliparous women has generated a lot of discussion and concern among childbearing women and those who care for them. Guest columnist Dr. Ginger Breedlove explains some of the issues and potential implications for clinical practice.
Ginger Breedlove is the Founder/Principal of Grow Midwives, LLC consulting firm in Shawnee Mission, KS, and past president of the American College of Nurse-Midwives. Dr. Breedlove can be reached at email@example.com.
The author declares no conflicts of interest.